Business Wire

FONDATION-IPSEN

23.5.2017 07:32:05 CEST | Business Wire | Press release

Share
The 16th Endocrine Regulations Prize of the Fondation IPSEN Will Be Awarded to Bruce McEWEN

The Fondation IPSEN (1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. The Fondation IPSEN Endocrine Regulations Prize (2) will be presented today at the ECE (European Congress of Endocrinology) in Lisbon. An international jury (3) chaired by Professor Iain Robinson (National Institute for Medical Research, London, UK ), awarded the prize to Bruce Mc Ewen for his pioneering work on glucocorticoids, stress and neuronal degeneration.

The Fondation IPSEN(1) contributes to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians from different backgrounds. Created in 2002, the Endocrine Regulations Prize(2) of the Fondation IPSEN awards renowned specialists who made breakthrough discoveries or significant progress in the field. Pr Bruce McEwen has been awarded by an international jury(3) for his pioneering work on glucocorticoids, stress and neuronal degeneration. The prize will be presented at the ECE (European Congress of Endocrinology), followed by a lecture given by Bruce McEwen.

During his talk, Bruce McEwen will discuss about the role of the steroid hormones that are produced in the brain which mediate every aspect of brain function. This has broadened the definition of ‘neuroendocrinology’ to include the reciprocal communication between the brain and the body via hormonal and neural pathways.
The brain is the central organ of stress and adaptation to stress because it perceives and determines what is threatening, as well as the behavioural and physiological responses to the stressor. The adult and developing brain possess remarkable structural and functional plasticity in response to stress, including neuronal replacement, dendritic remodelling, and synapse turnover. Stress causes an imbalance of neural circuitry subserving cognition, decision-making, anxiety and mood. This imbalance, in turn, affects systemic physiology via neuroendocrine, autonomic, immune and metabolic mediators. In the short term, as for increased fearful vigilance and anxiety in a threatening environment, these changes may be adaptive. But, if the danger passes and the behavioural state persists along with the changes in neural circuitry, such maladaptation may need intervention with a combination of pharmacological and behavioural therapies, as is the case for chronic anxiety and depression. Moreover, adverse early-life experience, produce lasting effects on brain and body over the life-course via epigenetic mechanisms. While prevention is most important, the plasticity of the brain gives hope for therapies that take into consideration brain–body interactions.

Biography
Bruce S. McEwen obtained his Ph.D. in Cell Biology in 1964 from The Rockefeller University. He is a member of the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He served as President of the Society for Neuroscience in 1997-98. As a neuroscientist and neuroendocrinologist, McEwen studies environmentally-regulated, variable gene expression in brain, mediated by circulating steroid hormones and endogenous neurotransmitters in relation to brain sexual differentiation and the actions of sex and stress hormones on the adult brain. His laboratory discovered adrenal steroid receptors in the hippocampus in 1968 that was the gateway for discovering effects of circulating hormones on cognitive function, mood regulation and other CNS functions. His laboratory combines molecular, anatomical, pharmacological, physiological and behavioral methodologies and relates their findings to human clinical information. His current research focuses on stress effects on amygdala and prefrontal cortex, as well as hippocampus, and his laboratory also investigates sex hormone effects and sex differences in these brain regions involved in cognitive function and mood regulation. He served on the MacArthur Foundation Research Network on Socioeconomic Status and Health, in which he has helped to reformulate concepts and measurements related to stress and stress hormones in the context of human societies. This led to the concept of “allostatic load and overload” that describes the wear and tear on the body and brain from chronic stress and related life style behaviors that lead to dysregulation of physiological stress pathways that are normally protective. He is also a member of the National Council on the Developing Child which focuses on biological embedding of early life experiences and promoting healthy brain development. He is the co-author of a book with science writer, Elizabeth Lasley, for a lay audience called “The End of Stress as We Know It”, published in 2002, and “The Hostage Brain” with science writer, the late Harold M. Schmeck, Jr., published in 1994.

(1) The Fondation IPSEN
Established in 1983 under the aegis of the Fondation de France, the ambition of the Fondation IPSEN is to initiate a reflection about the major scientific issues of the forthcoming years. The long-standing mission of the Fondation IPSEN is to contribute to the development and dissemination of scientific knowledge by fostering interaction between scientists and clinicians. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche , dedicated to three main topics: neurosciences, endocrinology and cancer science. Moreover the Fondation IPSEN has started several series of meetings in partnership with the Salk Institute, the Karolinska Institute as well as with the journals Cell and Science . The Fondation IPSEN produced several hundred publications and more than 250 scientists have been awarded prizes and grants.
www.fondation-ipsen.org

(2) The Endocrine Regulations Prize laureates
Created in 2002, this Prize of the Fondation Ipsen has been awarded to following the renowned specialists: Wylie VALE (2002), Robert LEFKOWITZ (2003), Pierre CHAMBON (2004), Thomas HÖKFELT (2005), Roger CONE (2006), William CROWLEY (2007), Ronald EVANS (2008), Gilbert VASSART (2009), Shlomo MELMED (2010), Paolo SASSONE-CORSI (2011), Jeffrey M. FRIEDMAN (2012), Bert O’MALLEY (2013), Maria I. NEW (2014), C. Ronald Kahn (2015) and John W. FUNDER (2016).

(3) Members of the jury
Iain ROBINSON (National Institute for Medical Research, London, UK) , President
Xavier BERTAGNA (Hôpital Cochin, Paris, France)
Felipe CASANUEVA (University of Santiago de Compostela, Santiago de Compostela, Spain)
Michael CONN (Texas Tech University Health Sciences Center, El Paso, USA)
Ezio GHIGO (Ospedale Molinette, Turin, Italy)
Ilpo HUHTANIEMI (Imperial College Faculty of Medicine, London, UK)
Gérard KARSENTY (Columbia University Medical Center, New York, USA)
Paul KELLY (Faculté de Médecine Necker Enfants Malades, Paris, France)
Stafford LIGHTMAN (University of Bristol, Bristol, UK)
Günter STALLA (Max Planck Institute of Psychiatry, München, Germany
Phyllis WISE (University of Illinois, Urbana, USA).

Contact:

Fondation IPSEN
Yannick TANGUY, Tel. : +33 (0)1 58 33 50 00
E-mail : fondation@ipsen.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wolters Kluwer Named Top Vendor Law Firm SaaS Solution Provider in the DACH Region for 202720.7.2026 09:00:00 CEST | Press release

Recognition highlights leadership position of Kleos in cloud-native legal practice management, earning the highest scores for customer satisfaction, value for money and customer recommendation among law firms in Germany, Austria and Switzerland. Wolters Kluwer’s Legal & Regulatory has been recognized as a top vendor for Law Firm SaaS Solutions in the DACH region for 2027, according to the latest Vendor Selection Matrix™ by Research in Action. Kleos, the company's cloud-native legal practice management platform, achieved a shared first-place position in the ranking and received the highest scores for customer satisfaction, value for money and customer recommendation among surveyed law firms in Germany, Austria and Switzerland. The recognition builds on the platform's earlier pan-European leadership position and reinforces Kleos' standing as one of Europe's leading legal practice management solutions. "We are proud to be recognized as a leading provider of Law Firm SaaS Solutions in the

IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release

A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines

Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release

Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca

STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release

STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye